Abstract:Mucosal barrier tissues and their mucosal associated lymphoid tissues (MALT) are attractive targets for vaccines and immunotherapies due to their roles in both priming and regulating adaptive immune responses. The upper and lower respiratory mucosae, in particular, possess unique properties: a vast surface area responsible for frontline protection against inhaled pathogens but also simultaneous tight regulation of homeostasis against a continuous backdrop of non-pathogenic antigen exposure. Within the upper and lower respiratory tract, the nasal and bronchial associated lymphoid tissues (NALT and BALT, respectively) are key sites where antigen-specific immune responses are orchestrated against inhaled antigens, serving as critical training grounds for adaptive immunity. Many infectious diseases are transmitted via respiratory mucosal sites, highlighting the need for vaccines that can activate resident frontline immune protection in these tissues to block infection. While traditional parenteral vaccines that are injected tend to elicit weak immunity in mucosal tissues, mucosal vaccines (i.e., that are administered intranasally) are capable of eliciting both systemic and mucosal immunity in tandem by initiating immune responses in the MALT. In contrast, administering antigen to mucosal tissues in the absence of adjuvant or costimulatory signals can instead induce antigen-specific tolerance by exploiting regulatory mechanisms inherent to MALT, holding potential for mucosal immunotherapies to treat autoimmunity. Yet despite being well motivated by mucosal biology, development of both mucosal subunit vaccines and immunotherapies has historically been plagued by poor drug delivery across mucosal barriers, resulting in weak efficacy, short-lived responses, and to-date a lack of clinical translation. Development of engineering strategies that can overcome barriers to mucosal delivery are thus critical for translation of mucosal subunit vaccines and immunotherapies. This review covers engineering strategies to enhance mucosal uptake via active targeting and passive transport mechanisms, with a parallel focus on mechanisms of immune activation and regulation in the respiratory mucosa. By combining engineering strategies for enhanced mucosal delivery with a better understanding of immune mechanisms in the NALT and BALT, we hope to illustrate the potential of these mucosal sites as targets for immunomodulation.

Parenteral vaccination strategies target protective immunity to the small and large intestine mucosa

Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract

Induction of Mucosal Immunity Through Systemic Immunization: Phantom or Reality?

Vaccine Strategies to Elicit Mucosal Immunity

Delivery strategies to enhance oral vaccination against enteric infections

Host Functional Response to a Prototypic Orally Delivered Self-Replicating Vaccine Platform

Nanovaccines Mediated Subcutis-to-Intestine Cascade for Improved Protection against Intestinal Infections

Multicomponent Pathogen-Mimicking Nanoparticles Induce Intestinal Immune Responses against Paratuberculosis

Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake

Mechanistic Insight into the TH1-Biased Immune Response to Recombinant Subunit Vaccines Delivered by Probiotic Bacteria-Derived Outer Membrane Vesicles

Probiotics, antibiotics and the immune responses to vaccines

mRNA Technology and Mucosal Immunization

Recombinant lactic acid bacteria as promising vectors for mucosal vaccination

Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

Mucosal delivery of native and recombinant protein vaccines against Trichostrongylus colubriformis

Mucosal Lactobacillus vectored vaccines.

Oral Gavage Delivery of PR8 Antigen with β-Glucan-Conjugated GRGDS Carrier to Enhance M-Cell Targeting Ability and Induce Immunity

Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis

Mucosal adjuvants

Advanced Oral Vaccine Delivery Strategies for Improving the Immunity

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria